PRECIGEN, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
PRECIGEN, INC. (PGEN) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$250.72 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-25
- PRECIGEN, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$250.72M.
- PRECIGEN, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$85.88M.
- PRECIGEN, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$93.52M.
- PRECIGEN, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2014 was -$83.26M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$250.72M 10-K · filed 2026-03-25 |
| 2024-12-31 | -$85.88M 10-K · filed 2026-03-25 |
| 2023-12-31 | -$93.52M 10-K · filed 2026-03-25 |
| 2014-12-31 | -$83.26M 10-K · filed 2015-03-02 |
| 2013-12-31 | -$39.25M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |